Akt: A Potential Drug Target for Metabolic Syndrome

Runyu Miao(Beijing University of Chinese Medicine), Xinyi Fang(Beijing University of Chinese Medicine), Jiahua Wei(Changchun University of Chinese Medicine), Haoran Wu(Beijing University of Chinese Medicine), Xinmiao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Jiaxing Tian(Chinese Academy of Medical Sciences & Peking Union Medical College)
Frontiers in Physiology
March 7, 2022
Cited by 77Open Access
Full Text

Abstract

The serine/threonine kinase Akt, also known as protein kinase B (PKB), is one of the key factors regulating glucose and lipid energy metabolism, and is the core focus of current research on diabetes and metabolic diseases. Akt is mostly expressed in key metabolism-related organs and it is activated in response to various stimuli, including cell stress, cell movement, and various hormones and drugs that affect cell metabolism. Genetic and pharmacological studies have shown that Akt is necessary to maintain the steady state of glucose and lipid metabolism and a variety of cellular responses. Existing evidence shows that metabolic syndrome is related to insulin resistance and lipid metabolism disorders. Based on a large number of studies on Akt-related pathways and reactions, we believe that Akt can be used as a potential drug target to effectively treat metabolic syndrome.


Related Papers

No related papers found

Powered by citation graph analysis